Compare Abbott India with NEULAND LABS - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs NEULAND LABS - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA NEULAND LABS ABBOTT INDIA/
NEULAND LABS
 
P/E (TTM) x 47.1 48.4 97.3% View Chart
P/BV x 15.2 3.7 415.5% View Chart
Dividend Yield % 0.5 0.1 457.9%  

Financials

 ABBOTT INDIA   NEULAND LABS
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
NEULAND LABS
Mar-20
ABBOTT INDIA/
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs8,834754 1,172.3%   
Low Rs5,458247 2,206.8%   
Sales per share (Unadj.) Rs1,731.1594.5 291.2%  
Earnings per share (Unadj.) Rs211.912.6 1,677.5%  
Cash flow per share (Unadj.) Rs219.937.0 594.1%  
Dividends per share (Unadj.) Rs65.002.00 3,250.0%  
Dividend yield (eoy) %0.90.4 227.6%  
Book value per share (Unadj.) Rs945.2553.4 170.8%  
Shares outstanding (eoy) m21.2512.83 165.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.10.8 490.3%   
Avg P/E ratio x33.739.6 85.1%  
P/CF ratio (eoy) x32.513.5 240.4%  
Price / Book Value ratio x7.60.9 835.9%  
Dividend payout %30.715.8 193.7%   
Avg Mkt Cap Rs m151,8486,421 2,365.0%   
No. of employees `0003.51.3 271.8%   
Total wages/salary Rs m4,3561,236 352.5%   
Avg. sales/employee Rs Th10,555.55,949.4 177.4%   
Avg. wages/employee Rs Th1,249.9963.8 129.7%   
Avg. net profit/employee Rs Th1,292.2126.4 1,022.1%   
INCOME DATA
Net Sales Rs m36,7867,627 482.3%  
Other income Rs m1,13339 2,916.1%   
Total revenues Rs m37,9197,666 494.6%   
Gross profit Rs m6,0471,019 593.5%  
Depreciation Rs m169313 54.1%   
Interest Rs m23216 10.4%   
Profit before tax Rs m6,989529 1,320.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,485367 676.9%   
Profit after tax Rs m4,503162 2,778.4%  
Gross profit margin %16.413.4 123.1%  
Effective tax rate %35.669.4 51.3%   
Net profit margin %12.22.1 576.1%  
BALANCE SHEET DATA
Current assets Rs m27,6105,152 535.9%   
Current liabilities Rs m8,5693,576 239.6%   
Net working cap to sales %51.820.7 250.6%  
Current ratio x3.21.4 223.7%  
Inventory Days Days60105 57.3%  
Debtors Days Days2791 30.1%  
Net fixed assets Rs m1,0573,969 26.6%   
Share capital Rs m213129 164.7%   
"Free" reserves Rs m19,8736,971 285.1%   
Net worth Rs m20,0867,100 282.9%   
Long term debt Rs m0774 0.0%   
Total assets Rs m29,40912,310 238.9%  
Interest coverage x311.63.5 9,023.9%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.30.6 201.9%   
Return on assets %15.43.1 501.4%  
Return on equity %22.42.3 982.1%  
Return on capital %34.99.5 368.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3695,187 7.1%   
Fx outflow Rs m4,9181,593 308.8%   
Net fx Rs m-4,5493,594 -126.6%   
CASH FLOW
From Operations Rs m4,991573 870.5%  
From Investments Rs m-2,570-487 527.9%  
From Financial Activity Rs m-1,428-55 2,605.8%  
Net Cashflow Rs m99333 3,046.9%  

Share Holding

Indian Promoters % 0.0 36.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 63.7 12.4%  
FIIs % 0.1 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 63.7 26.8%  
Shareholders   18,270 12,705 143.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare ABBOTT INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Nifty is Weak but Smallcaps Can Outperform(Momentum Moves)

The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 26, 2021 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - ASTRAZENECA PHARMA COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS